Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alvotech - Ordinary Shares (NQ: ALVO ) 13.12 +0.35 (+2.74%) Streaming Delayed Price Updated: 9:37 AM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Alvotech - Ordinary Shares < Previous 1 2 3 4 5 Next > Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET October 30, 2024 From Alvotech Via GlobeNewswire Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 October 25, 2024 From Alvotech Via GlobeNewswire European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® October 10, 2024 From Alvotech Via GlobeNewswire Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® September 25, 2024 From Alvotech Via GlobeNewswire Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 26, 2024 From Alvotech Via GlobeNewswire Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 August 15, 2024 From Alvotech Via GlobeNewswire European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) August 15, 2024 From Alvotech Via GlobeNewswire Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET August 01, 2024 From Alvotech Via GlobeNewswire STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe July 22, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Closing of Private Debt Financing July 11, 2024 From Alvotech Via GlobeNewswire Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 Via MarketBeat Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® July 02, 2024 From Alvotech Via GlobeNewswire Alvotech Issues New Shares to Holders of Convertible Bonds July 01, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 July 01, 2024 From Alvotech Via GlobeNewswire Alvotech Receives Conversion Notices for Majority of Convertible Bonds June 26, 2024 From Alvotech Via GlobeNewswire Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe June 18, 2024 From Alvotech Via GlobeNewswire Alvotech and STADA add to strategic alliance through denosumab partnership June 11, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Strategic Refinancing Agreement June 07, 2024 From Alvotech Via GlobeNewswire 2 Generic Drug Makers With Growing Runways May 31, 2024 Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Via MarketBeat Topics Intellectual Property Exposures Intellectual Property Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 May 29, 2024 From Alvotech Via GlobeNewswire Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update May 21, 2024 From Alvotech Via GlobeNewswire Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) May 13, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 May 02, 2024 From Alvotech Via GlobeNewswire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) April 24, 2024 From Alvotech Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
